Blephamide Eye Drops

Quick links to important sections

Blephamide Eye Drops

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Blephamide Eye Drops

Quick Facts

Property Description
Active ingredient Sulfacetamide and Prednisolone
Form Sterile Ophthalmic Suspension, Solution, or Ointment
Pharmacological class Ophthalmic Anti-infective and Corticosteroid Combination
General purpose Alleviation of inflammation and control of bacterial risk
Origin Synthetic

What is Blephamide Eye Drops?

Blephamide Eye Drops, or its generic equivalent, the Sulfacetamide and Prednisolone Ophthalmic Combination, is a prescription-only ophthalmic medicine that belongs to the Ophthalmic Anti-infective and Corticosteroid Combination pharmacological class. This formulation is clinically recognized for its ability to target complex ocular conditions where both inflammation and bacterial involvement are concerns. The medicine is prepared as a sterile formulation for safe, topical ophthalmic administration.

Composition and Pharmaceutical Form

This medicine's structure is defined by its two key components: the sulfonamide antibacterial agent Sulfacetamide and the potent corticosteroid Prednisolone. This combination is structurally distinct due to the use of a sulfa-based antibiotic with a glucocorticoid, differentiating it from other ophthalmic combination products. The medicine is supplied in sterile ophthalmic dosage form(s), typically as a suspension or solution, and may also be available as an ophthalmic ointment. The topical ophthalmic route is essential for ensuring appropriate localized effect on the eye's external surface.

The General Purpose of the Combination

The primary general purpose of this combination medicine is to provide simultaneous alleviation of physical discomfort and control of potential bacterial growth in the eye. The Prednisolone component works to suppress the inflammatory response, which is a key cause of redness and irritation. Concurrently, Sulfacetamide applies a bacteriostatic effect by restricting the synthesis of folic acid in susceptible bacteria, thereby limiting their ability to multiply. This dual action provides a robust, pre-emptive strategy for managing inflammation while mitigating the microbiological risk associated with certain inflammatory ocular conditions.

What side effects are possible with Blephamide Eye Drops?

Possible Side Effects and Safety Information

This section details officially documented adverse effects and safety characteristics of the Sulfacetamide and Prednisolone Ophthalmic Combination, based strictly on government regulatory sources.


Ocular and Systemic Adverse Reactions

The most commonly listed adverse reactions are ocular, often related to the corticosteroid component (Prednisolone), or local irritation. Rare, but severe, systemic reactions are documented for the sulfonamide component (Sulfacetamide).

System-Organ Class Common Adverse Reactions Serious Adverse Reactions (Rare)
Eye Disorders Eye irritation, Eye pain, Ocular hyperemia, Blurred vision Elevated Intraocular Pressure (IOP)/Glaucoma, Cataract formation, Optic nerve damage
Immune/Skin Disorders Hypersensitivity reactions Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN)
Blood Disorders Agranulocytosis, Aplastic Anemia

Duration- and Population-Related Safety Notes

Duration of Use: The regulatory label specifies that use for 10 days or longer carries an increased risk of developing ocular hypertension and cataracts. Routine intraocular pressure monitoring is required with extended use.

Contraindications and Restrictions: The medicine is contraindicated in specific conditions, including most viral diseases (e.g., Herpes Simplex Keratitis), fungal diseases, and mycobacterial infections of the eye. Individuals with a known hypersensitivity to sulfonamides or corticosteroids should not use this product.

Specific Populations: Safety and effectiveness have not been established in children younger than 6 years of age. For lactating women, a concern is documented regarding the potential for the sulfonamide component to cause kernicterus in infants.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information for Sulfacetamide and Prednisolone ophthalmic preparations distinguishes between topical overuse and the more significant risk of accidental ingestion.

Overdose Scope

Domain Official Regulatory Context
Documented Manifestation Topical overdose by the ophthalmic route is not ordinarily expected to cause acute problems.
Key Exposure Factor The primary concern is accidental ingestion of the solution or ointment, which increases the potential for systemic exposure to the active components.
Severe Outcomes Fatalities have occurred, although rarely, due to severe systemic reactions to sulfonamides, including Stevens-Johnson syndrome, aplastic anemia, and fulminant hepatic necrosis.
Specific Risk Note Systemically administered sulfonamides are capable of producing kernicterus in infants if the drug is used by a lactating woman.

Emergency Actions Mandated by Regulators

Immediate medical help is required if the medication is accidentally swallowed. Patients must contact a healthcare professional, hospital emergency department, or regional Poison Control Centre immediately, and this action is mandated even if there are no symptoms following the ingestion. For suspected topical overuse, the official guidance involves flushing or washing the eye with water.

Summary of Regulatory Profile

Regulatory documents define the overdose profile by focusing on the low local risk versus the systemic risk from ingestion, explicitly requiring urgent contact with emergency services upon known or suspected swallowing due to the potential for rare, severe systemic reactions associated with the sulfonamide component.

Therapeutic Uses of Blephamide Eye Drops

What Blephamide Eye Drops treats: Main Uses and Benefits

This ophthalmic combination is commonly used for corticosteroid-responsive inflammatory ocular conditions where a superficial bacterial ocular infection or a risk of infection exists. The medicine is considered relevant in the management of dual-pathology conditions, including certain presentations of blepharitis, conjunctivitis, and keratitis.

Easing Symptoms of Acute Ocular Discomfort

It provides support in managing symptoms related to inflammatory or irritative states such as pronounced eye redness, tissue swelling, burning, and pain. This application may assist with maintaining functional stability and supports general well-being during symptomatic phases. In clinical scenarios following ocular trauma or specific eye surgeries, the medication is applied as supportive care to manage symptoms related to inflammatory states and contexts involving a risk of infection.

Quick Fact: Symptomatic Support in Combined Ocular Conditions

  • Conditions managed: Steroid-responsive inflammation complicated by potential superficial bacterial infection.
  • Symptom domains addressed: Acute ocular discomfort, redness, and swelling.
  • Patient benefit: Provides support that helps ease the overall symptom burden and assists with maintaining functional stability.

Regulatory References

  1. DailyMed Ophthalmic Solution Indications

Eligibility and Restrictions for Use

Who Can and Cannot Use Blephamide Eye Drops?

Regulatory documents strictly define the eligibility for Blephamide Eye Drops (Sulfacetamide Sodium and Prednisolone Acetate Ophthalmic Suspension), primarily through absolute contraindications and age-based limitations.


Contraindicated Populations

Use of this medicine is formally prohibited for the following populations, as stated in official labeling:

  • Individuals with known or suspected hypersensitivity to any component, including sulfonamides.
  • Patients with most active viral diseases of the cornea and conjunctiva, such as Epithelial Herpes Simplex Keratitis (dendritic keratitis), Vaccinia, or Varicella.
  • Patients with mycobacterial infection or fungal diseases of the ocular structures.
  • Patients with acute purulent untreated infections of the eye.

Age and Physiological Restrictions

Category Regulatory Status
Children Under 6 Years Safety and effectiveness have not been established; use is not permitted.
Pregnancy Classified as Category C; use is only permitted if the potential benefit justifies the potential risk to the fetus due to potential risks from the sulfonamide component.
Lactation Not recommended, as sulfonamides are excreted in human milk.
Glaucoma Requires conditional use with mandatory monitoring of intraocular pressure (IOP) if treatment exceeds 10 days.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documentation for the Sulfacetamide and Prednisolone ophthalmic combination primarily addresses a pharmacokinetic interaction related to the systemic risk of the Prednisolone component. This interaction involves medicinal products classified as CYP3A inhibitors, which are substances that interfere with the metabolic clearance of the corticosteroid.

Co-treatment with CYP3A inhibitors is formally documented to increase the systemic exposure of Prednisolone, which carries an expected risk of heightened systemic corticosteroid side-effects. The regulatory restriction advises that co-administration should be avoided unless the official benefit-risk assessment specifically supports the combination. Cobicistat-containing products are explicitly listed as an example of a potent CYP3A inhibitor relevant to this exposure-modifying pattern.


Interaction Type Interacting Substance/Class Official Interaction Outcome
Pharmacokinetic CYP3A Inhibitors Increases systemic exposure of Prednisolone
Restriction Cobicistat-containing products Co-administration is advised to be avoided

No mandatory timing separation rules are explicitly listed as an interaction-based restriction in primary regulatory labels for this product. Furthermore, official documentation does not list specific interactions with food, alcohol, herbal products, or supplements.

Mechanism of Action

Blephamide's mechanism relies on the dual action of sulfacetamide and prednisolone. Sulfacetamide functions as a competitive inhibitor of the bacterial enzyme dihydropteroate synthase. This interaction prevents the incorporation of p-aminobenzoic acid ( PABA) into the synthesis of dihydrofolic acid ( DHF) . The resulting DHF deficiency subsequently inhibits the bacterial synthesis of purines and nucleic acids (DNA/RNA).

Prednisolone, a synthetic glucocorticoid, exerts its effects by binding to the cytosolic glucocorticoid receptor ( GR). The prednisolone- GR complex translocates to the cell nucleus, where it acts as a transcription factor, interacting with glucocorticoid response elements ( GREs) to modulate gene expression. This nuclear action leads to the downregulation of genes encoding pro-inflammatory mediators, such as cytokines and chemokines. The systemic effect includes inhibiting the enzyme phospholipase A2 ( PLA2) and stabilizing lysosomal membranes, which suppresses the release of inflammatory mediators like prostaglandins and histamine.

Dosage and Administration Information

How to Use Blephamide Eye Drops

The administration of the sulfacetamide and prednisolone combination is strictly by the topical ophthalmic route (on the eye surface) using the specific sterile dosage forms provided, and is not intended for injection. Its usage pattern is characterized by a frequent, standardized regimen for initial control of acute conditions.

Standard Dosing Regimens and Frequency

The specific regimen is determined by the pharmaceutical form prescribed:

  • Ophthalmic Suspension or Solution: The standard regimen involves the instillation of two drops into the affected eye(s). This is typically administered with a high frequency of every four hours throughout the day and once at bedtime.
  • Ophthalmic Ointment: For the ointment formulation, the regimen consists of applying a small amount (approximately a 1/2 inch ribbon) into the affected eye(s) three or four times per day, supplemented by one or two applications at night.

Administration Procedures and Course Duration

Preparation and Co-Administration

To ensure even dispersion of the active ingredients, the Ophthalmic Suspension requires the bottle to be shaken well before using. If other ophthalmic medications are used concurrently, a minimum of five minutes must elapse between applications.

Duration and Renewal

Treatment is intended to be short-term and is subject to strict limits; the initial prescription quantity should not exceed 20 milliliters (suspension/solution) or 8 grams (ointment). A procedural requirement dictates that renewal beyond this initial quantity must be made by a physician after re-examination of the patient with the aid of magnification. If the condition requires prolonged use, therapy withdrawal is managed by gradually decreasing the application frequency (tapering).

Population-Specific Use

The standard dosing regimens are applied to adults and children aged six years and older. The safety and effectiveness of this combination in pediatric patients below the age of two months have not been established.

Recent Clinical Evidence

Research evidence / Overview of studies for Blephamide Eye Drops

Evidence for Use in Inflammatory Ocular Conditions with Bacterial Risk

Research explored the combination of a steroid and an antibacterial agent (Sulfacetamide and Prednisolone) in contexts where the eye is inflamed and there is a risk of, or an existing, superficial bacterial presence. Studies were conducted during periods of increased symptom activity and primarily used short-term randomized controlled trials (RCTs). These trials was evaluated in groups of Adults and Adolescents to observe data show patterns related to the main clinical outcomes.

The studies examined outcomes linked to inflammatory or irritative states using standardized assessment scores, as well as patient-reported outcomes describing perceived discomfort. Research also monitored microbiological metrics and bacterial culture results, and data show patterns related to the status of bacteria in the observed populations. However, the research exploring short-term symptom changes was associated with limited follow-up durations.

Research on Specific Anterior Segment Conditions

The evidence base was evaluated in studies for specific conditions of the front of the eye, including Blepharitis, Conjunctivitis, and certain forms of Keratitis. Studies explored patient groups presenting with cycles of stability and flare-ups, monitoring how symptoms evolved in the observed populations. Research examined outcomes related to physical discomfort and outcomes reflecting daily functioning or activity level.

Long-Term Outcomes and Follow-Up Data

The majority of pivotal studies utilized short-term observation periods, typically lasting up to 10 or 14 days. These studies primarily focused on assessing acute changes and the evolution of symptoms and signs. Consequently, long-term effects are not fully established. There is limited information for outcomes that describe functional stability or disease control extending over several months or years. Evidence exploring longer-term symptom patterns following the cessation of short-term treatment remains insufficient.

Evidence in Special Populations and Research Gaps

Specific clinical studies research explored short-term symptom changes in Children aged 6 years and older. However, the current evidence structure indicates that data for certain groups remain insufficient. For instance, the safety and efficacy research has not been established for children younger than 6 years. Certainty remains low in specific areas; comparative evidence is lacking that conclusively explores how this specific combination was studied alongside all newer ophthalmic combination products for the same indications.

Frequently Asked Questions (FAQ)

Common questions about Blephamide Eye Drops (FAQ)


Q: What does 'ophthalmic suspension' mean for eye drops like Blephamide?

Official documents describe a suspension as a liquid that contains fine particles of the medicine that are not fully dissolved. Because the active ingredients are suspended, regulatory administration instructions note that the bottle should be shaken well before use to ensure the medicine is evenly dispersed in each drop.


Q: Why is Blephamide prescribed when some people get simple pink eye?

Official documents state the medicine is a combination designed to address both ocular inflammation, which causes redness and irritation, and the presence or risk of susceptible bacterial infection. This dual action strategy is used for certain mixed ocular conditions where both issues are a concern.


Q: Can Blephamide make my eyes more sensitive to light?

Official adverse reaction reporting includes common effects such as ocular irritation and eye pain. If an individual experiences new or worsening sensitivity to light, consulting a healthcare professional for guidance is recommended.


Q: What is the risk of getting an eye infection after using these drops?

Regulatory warnings state that using corticosteroid eye drops, especially over extended periods, may potentially increase the risk of a secondary fungal or viral eye infection. The medicine is contraindicated (formally prohibited) if certain existing fungal or viral infections are present.


Q: Can I wear contact lenses while I'm using Blephamide?

Regulatory guidance indicates that the use of soft contact lenses is not advised while using this medicine. This restriction is often due to the potential for the preservative in the drops to be absorbed by the lens material. Lenses may typically be reinserted after a specified time following the final administration.


Q: Do I have to avoid certain activities while using Blephamide?

The official patient information notes that temporary blurred vision is a possible side effect. If this effect is experienced, regulatory documents suggest patients should exercise caution when performing activities requiring clear vision, such such as driving or operating machinery.


Q: Does Blephamide treat the cause of the problem, or just the symptoms?

The medicine is a combination designed to work in two ways. The antibacterial component, Sulfacetamide, is described as working against susceptible bacteria, which addresses a potential cause of the condition. Concurrently, the corticosteroid component, Prednisolone, suppresses the inflammatory response to address symptoms like redness and discomfort.


Q: Is Blephamide the drop people use for inflammation after eye surgery?

Official indications cover various corticosteroid-responsive inflammatory ocular conditions where a risk of superficial bacterial infection exists. The medicine may be used under a healthcare professional's guidance for inflammatory states, including those following certain procedures.


Q: What happens if I forget to use a dose of Blephamide?

Regulatory documents and patient information leaflets include specific guidance for managing missed doses. This guidance typically directs patients on whether to take the dose when remembered or to skip it and continue the regular schedule. Double doses are formally warned against.


Q: Are there any common over-the-counter products that interact with Blephamide?

Official interaction documentation does not list specific interactions with typical non-prescription medicines, food, or alcohol. However, official documentation notes that a minimum five-minute separation should be maintained when administering this medicine and any other drops used in the eye.


Q: Why is Blephamide only available by prescription?

The medicine is classified as prescription-only because it contains a potent corticosteroid (Prednisolone) and an antibacterial agent (Sulfacetamide). Regulatory bodies require the drug to be used under strict medical supervision due to risks like elevated eye pressure and the potential for secondary infections.


Q: What does the research say about Blephamide's use in chronic eye conditions?

Clinical studies detailed in regulatory files primarily utilized short-term observation periods, typically up to 10 or 14 days. The evidence regarding the functional stability or control of conditions extending over several months or years is described as limited.


Q: How is Blephamide different from other steroid-antibiotic combination drops?

The medicine is structurally distinct due to its combination of the steroid Prednisolone with the specific sulfonamide antibacterial agent Sulfacetamide. Other ophthalmic combination drops may contain different classes of antibiotics or different types of steroids.


Q: Is Blephamide used for styes or just for more widespread infections?

Official indications focus on conditions such as Blepharitis, Conjunctivitis, and Keratitis where inflammation and risk of bacterial infection are present. The medicine is generally used for conditions caused by bacteria susceptible to the sulfacetamide component.


Q: Why do official documents mention potential for fungal infections with Blephamide use?

Regulatory documents mention this potential because the corticosteroid component can suppress the body's natural defenses against non-bacterial organisms. This effect may allow for the growth and establishment of fungal infections if they are already present or introduced.


Q: Does Blephamide need to be refrigerated?

Official storage guidelines require the medicine to be stored at a temperature between 8 C and 24 C (46 F and 75 F). Official guidelines state that the medicine should not be frozen. This range is generally described as cool room temperature storage.


Q: What should I do if the drop bottle tip touches my eye?

Official administration instructions include warnings intended to prevent the dropper tip from contacting the eye, fingers, or any other surface. This warning is included to prevent contamination of the solution, which could potentially lead to a secondary eye infection.


Q: Are there any restrictions on driving while using Blephamide?

Because temporary blurred vision is a commonly reported side effect, official patient information suggests that caution should be exercised when driving or operating potentially hazardous machinery until vision is clear.


Q: What are the ingredients that are inactive in Blephamide Eye Drops?

Official documents list the inactive ingredients (excipients) used in the formulation in addition to the active drug components. These typically include substances such as a preservative (like benzalkonium chloride), stabilizing agents, and purified water.


Q: Are there different strengths or versions of Blephamide available?

Yes, the medicine is described in regulatory documents as being available in different dosage forms, including an ophthalmic suspension, solution, and ointment. While each contains the same active ingredients, the specific concentrations (strengths) may vary by formulation.


Q: Why do official guidelines stress not sharing these drops with anyone?

Official guidance includes warnings intended to prevent the sharing of the medicine with others because it is a sterile, prescription-only product used to treat a specific medical condition. Sharing the eye drops can lead to the spread of infection or incorrect use.


Q: Does Blephamide interact with oral contraceptives or blood thinners?

Official interaction documentation for this ophthalmic combination primarily focuses on a pharmacokinetic risk involving CYP3A inhibitors, which increase steroid exposure. No specific, mandatory warnings related to common oral contraceptives or blood thinners are consistently listed across all regulatory labels.


Q: Can long-term use of Blephamide lead to eye dependence on the drops?

Official administration instructions note that if the condition requires prolonged use, therapy withdrawal is managed by gradually decreasing the application frequency, or tapering. Tapering is a standard measure for corticosteroids to prevent a rebound of symptoms upon sudden discontinuation.

How should Blephamide Eye Drops be stored and disposed of?

How to Store and Dispose of Blephamide Ophthalmic Suspension

Blephamide (sulfacetamide sodium and prednisolone acetate ophthalmic suspension) must be stored under specific environmental and container conditions as mandated by official labeling.

Storage Requirements

Condition Requirement
Temperature Store between 8°C and 24°C (46°F and 75°F). Do not freeze.
Protection Keep the container tightly closed and stored in an upright position. Protect from light.
Stability Check Do not use the solution if it has darkened in color; discard immediately. Yellowishness is noted as generally not affecting activity.
Child Safety Keep out of the sight and reach of children.

Disposal Instructions

All unused product and containers must be disposed of in accordance with local regulations. Official guidance recommends using a drug take-back location when available, or following instructions for safe disposal in the household trash for medicines not on the FDA's Flush List.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Blephamide Eye Drops found in:

A-Z Index: